Re-emergence of fibrates in the management of dyslipidemia and cardiovascular risk (Q34107307)

31 July 2017

1 reference

title

Re-emergence of fibrates in the management of dyslipidemia and cardiovascular risk (English)

1 reference

31 July 2017

1 reference

1 reference

Linton MF

1

1 reference

PubMed ID

11122722

31 July 2017

Fazio S

series ordinal

2

1 reference

31 July 2017

1 January 2000

1 reference

Current Atherosclerosis Reports

31 July 2017

1 reference

31 July 2017

2

1 reference

31 July 2017

1

1 reference

31 July 2017

29-35

1 reference

https://scigraph.springernature.com/pub.10.1007/s11883-000-0092-2

31 July 2017

0 references

cites work

Fibrates influence the expression of genes involved in lipoprotein metabolism in a tissue-selective manner in the rat

1 reference

https://api.crossref.org/works/10.1007%2FS11883-000-0092-2

Mechanism of action of fibrates on lipid and lipoprotein metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-000-0092-2

PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-000-0092-2

Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-000-0092-2

Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-000-0092-2

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

21 January 2018

1 reference

12 December 2020

Peroxisome proliferator-activated receptor alpha in metabolic disease, inflammation, atherosclerosis and aging

1 reference

12 December 2020

Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor

1 reference

12 December 2020

Gemfibrozil. A reappraisal of its pharmacological properties and place in the management of dyslipidaemia

1 reference

12 December 2020

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

1 reference

12 December 2020

Drug treatment of lipid disorders

1 reference

12 December 2020

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

1 reference

12 December 2020

Identification of multiple dense LDL subfractions with enhanced susceptibility to in vitro oxidation among hypertriglyceridemic subjects. Normalization after clofibrate treatment

1 reference

12 December 2020

Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates

1 reference

12 December 2020

Beneficial effects of fibrates on apolipoprotein A-I metabolism occur independently of any peroxisome proliferative response

1 reference

12 December 2020

Micronised fenofibrate: a review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia

1 reference

12 December 2020

Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study

1 reference

12 December 2020

Consensus for the use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease. Fibrate Consensus Group

1 reference

12 December 2020

Fenofibrate and LDL metabolic heterogeneity in hypercholesterolemia

1 reference

12 December 2020

W.H.O. cooperative trial on primary prevention of ischaemic heart disease using clofibrate to lower serum cholesterol: mortality follow-up. Report of the Committee of Principal Investigators

1 reference

12 December 2020

Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS)

1 reference

12 December 2020

Modulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III

1 reference

12 December 2020

Comparative efficacy and safety of micronized fenofibrate and simvastatin in patients with primary type IIa or IIb hyperlipidemia

1 reference

12 December 2020

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

1 reference

12 December 2020

High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study

1 reference

12 December 2020

Comparison of the efficacy and safety of fenofibrate and lovastatin in patients with primary type IIa or IIb hyperlipidaemia

1 reference

12 December 2020

Retardation of coronary atherosclerosis: the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT) and other angiographic trials

1 reference

12 December 2020

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

1 reference

12 December 2020

Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid

1 reference

12 December 2020

Fenofibrate reduces plasma cholesteryl ester transfer from HDL to VLDL and normalizes the atherogenic, dense LDL profile in combined hyperlipidemia

1 reference

12 December 2020

Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico

1 reference

12 December 2020

Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy

1 reference

12 December 2020

Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group

1 reference

12 December 2020

Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression

1 reference

12 December 2020

Cardiovascular risks: New insights from Framingham

1 reference

12 December 2020

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

1 reference

12 December 2020

Regulation of apo A-I gene expression by fibrates.

1 reference

12 December 2020

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

1 reference

12 December 2020

PPARalpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene

1 reference

12 December 2020

Hotline sessions at the 20th European Congress of Cardiology

1 reference

12 December 2020

Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators.

1 reference

12 December 2020

Hypertriglyceridemia as a cardiovascular risk factor

1 reference

12 December 2020

Transcriptional control of triglyceride metabolism: fibrates and fatty acids change the expression of the LPL and apo C-III genes by activating the nuclear receptor PPAR.

1 reference

12 December 2020

Multicenter comparison of micronized fenofibrate and simvastatin in patients with primary type IIA or IIB hyperlipoproteinemia

1 reference

12 December 2020

Pathophysiology and management of low high-density lipoprotein cholesterol

1 reference

12 December 2020

10.1007/S11883-000-0092-2

Identifiers

DOI

1 reference

PubMed ID

11122722

Dimensions Publication ID

31 July 2017

0 references

1 reference

PubMed ID

11122722